Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001596468-26-000004·AN2 Therapeutics, Inc.
Schedule 13G ownership disclosure
AN2 Therapeutics, Inc.
Common Stock and Warrants · CUSIP: 037326105
Event date: 2025-12-31
- Filing-level shares
- 2,975,164.00
- Percent of class
- 5.4%
- Almitas Capital LLC
Shares: 2,975,164.00 · Class: 5.4%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001596468-26-000004
- Form type
- SCHEDULE 13G
- Filer
- AN2 Therapeutics, Inc.
- CIK
- CIK 1880438
- Filed
- Feb 17, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership